Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatosis of Liver Clear all
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

NCT02421094
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 13, 2026, 4:47 PM EDT
Withdrawn No phase listed Observational

Assessment of Fatty Liver With Thermo-acoustic Device

NCT04302051
View directory record Official record
Conditions
NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
Interventions
Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 4:47 PM EDT
Enrolling by invitation No phase listed Observational

Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00983463
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899
View directory record Official record
Conditions
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
83
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

NCT00706537
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH)
Interventions
Active treatment, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Anaheim, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 13, 2026, 4:47 PM EDT
Not yet recruiting Not applicable Interventional

Effects of Whole Fruit on Blood Sugar in People With Type 2 Diabetes

NCT07376226
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Whole Fruit
Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 13, 2026, 4:47 PM EDT
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

NCT03784716
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Liver Diseases
Interventions
Ketogenic Diet, Standard Weight Loss Diet
Other
Lead sponsor
Marc Goodman
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 13, 2026, 4:47 PM EDT
Suspended Phase 2 Interventional Results available

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

NCT00546455
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Fenretinide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2099
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

NCT02856555
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Firsocostat, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Coronado, California • Foster City, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 13, 2026, 4:47 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Pathology of Pediatric NAFLD

NCT05430178
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions
Oral sugar tolerance test, De novo lipogenesis test, Gluconeogenesis test
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
10 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Cholic Acid for Hepatic Steatosis in Lipodystrophy

NCT00457639
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
Cholic Acid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Impact of Weight Loss Surgery in Adolescents With NAFLD

NCT02952170
View directory record Official record
Conditions
NAFLD, Obesity, Adolescent
Interventions
MRI
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 22 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 13, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis

NCT01188083
View directory record Official record
Conditions
Non-alcoholic Fatty-liver Disease
Interventions
Fructose Drink, Glucose Drink
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Comparison of Dietary Sugar Reduction Methods

NCT04186793
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Guided Grocery Shopping (GGS), Diet Provision Group
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 13, 2026, 4:47 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
169
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 4:47 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 13, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH

NCT02314026
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Forts Sam Houston, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 13, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

High Fructose Diet, the Gut Microbiome, and Metabolic Health

NCT06329544
View directory record Official record
Conditions
MASLD, Type 2 Diabetes, Obesity
Interventions
Fructose, glucose
Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
25 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 13, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 13, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet

NCT03141008
View directory record Official record
Conditions
Obesity, Fatty Liver, Ketogenic Dieting
Interventions
Fibroscan changes with different diets
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 13, 2026, 4:47 PM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 13, 2026, 4:47 PM EDT